Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Sponsor: Exosome Diagnostics, Inc.
Listed as NCT03236675, this observational or N/A phase trial focuses on Carcinoma, Non-Small-Cell Lung and remains ongoing. Sponsored by Exosome Diagnostics, Inc., it has been updated 12 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Oct 2023 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Dec 2021 — Oct 2023 [monthly]
Active Not Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Mar 2019 — Nov 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Exosome Diagnostics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .